Compared to developed nations, Canadian public drug plans provide less
access to new medicines and vaccines - Rx&D calls for new dialogue
TORONTO, Nov. 28, 2011 /CNW/ - Despite the demonstrated benefits of new
medicines and vaccines to improve health outcomes and help sustain our
health care system, Rx&D's 2010-11 International Report on Access to Medicines (IRAM) released today finds that Canada's public drug plans continue to
provide less access to new medicines and vaccines compared to 31 other
"The 2010-11 IRAM aims to promote a dialogue with our health partners about how we can
leverage the full value of innovation to offer better access and ensure
sustainable health care for all Canadians," said Russell Williams,
President of Rx&D.
Rx&D's 2010-2011 IRAM compares how drug plans in Canada and 31 OECD countries are publicly
reimbursed. The report considers a total of 173 drugs covering 213
indications for medicines introduced between 2004 and December 2010.
Key findings include:
The Canadian Positive Listing Percentage average is 48%, compared to
83.5% for the other 31 OECD countries (ranging from just above 32% in
Estonia to 100% in 6 other OECD countries);
The Canadian listing average is also below all 31 OECD countries for 15
specific diseases areas not related to cancer such as arthritis,
cardiovascular, diabetes, infectious diseases and mental health; and,
Canada ranks 31st of 32 countries for first-in-class drugs.
Public Drug Plans and Our Collective Opportunity
Canadians are living with unprecedented rates of complex, chronic
disease across all age groups. It is driving demand for health care
services and support, creating real challenges for health care system
quality and sustainability.
Public drug plans are a critical element of our health care system, and
appropriately prescribed innovative medicines and vaccines play a key
role in sustaining it. They help patients live longer and lead more
productive lives. They also contribute to the sustainability of our
health care system by reducing surgeries, hospitalizations and other
health, economic and social costs.
Rx&D's 2010-2011 IRAM proposes six principles that could form the basis for a public dialogue
to provide better access to innovative health care options: putting
patients first; promoting the appropriate use of medicines; making
clinical and therapeutic choice paramount; ensuring that financial
hardship is not a barrier to receiving appropriate care; enshrining
innovation as a guiding principle of our healthcare system; and
recognizing the value of pharmaceuticals in improving patient health
outcomes and contributing to a sustainable healthcare system.
Rx&D's 2010-2011 International Report on Access to Medicines
Rx&D's 2010-2012 IRAM compares how drug plans in Canada and 31 OECD
countries are publicly reimbursed. The report considers a total of 173
drugs covering 213 indications for medicines introduced between 2004
and December 2010.
Overall Findings (173 drugs representing 213 indications in the
The Canadian Positive Reimbursement Percentage average is 48% compared
to 83.5% for the other 31 OECD countries (ranging from just above 32%
in Estonia to 100% in 6 OECD countries).
Canada's Positive Reimbursement Percentage average has hovered around
50% over the past 7 years.
57% of cancer drugs are covered publicly in Canada (50 cancer drugs
covering 71 indications were studied) compared to an average of 79.9%
for the other 31 OECD countries (ranging from a just below 23.5% in
Austria to a high of 100% in 8 OECD countries).
Disease Comparisons (Other than cancer)
In nine of 15 disease areas, Canada's public drug plan reimbursement is
greater than 50%.
In 13 of 15 disease areas, Canada's public drug plan reimbursement falls
far behind that of other OECD countries.
First-in-Class Drugs (55 first-in-class drugs covering 72 indications)
Canada ranks 31st out of 32 countries when it comes to access to
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
To view the report, please visit www.canadapharma.org
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: